Nancy Reau, MD
Gastroenterology · Burr Ridge, ILNPI 1164585683
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $247,757 of the $357,164 with a category attached, or 69.4%. 39 manufacturers reported payments, led by Gilead at 50.4% of the total. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 487 payments — averaging $733.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$180K
- AbbVie$53K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$50K
- Novo Nordisk$26K
- Intercept Pharmaceuticals, Inc.$19K
- Mallinckrodt Hospital Products Inc.$8K
- plus $21K from 33 others
Across 155 payments — averaging $2608.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eiger Biopharmaceuticals, Inc.$187K
- AbbVie$107K
- Bausch Health US, LLC$88K
- Perspectum Diagnostics Ltd$17K
- Janssen Research & Development, LLC$4K
- Shire North American Group Inc$1K
- plus $1K from 1 others
What the payments were for
- Consulting fees$247,75769%
- Speaking & faculty fees$39,55411%
- Travel & lodging$59,59117%
- Food & beverage$10,2513%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavyret$39,266
- XIFAXAN$28,437
- Epclusa$22,950
- OCALIVA$13,760
- Viekira Pak$11,372
- TERLIVAZ$6,285
- Vemlidy$5,630
- OPDIVO$4,326
- Architect$2,975
- Architect system$1,596
- FibroScan$1,515
- TE7 MAX$1,500
- REZDIFFRA$254
- AXIOS$162
- THERASPHERE-BIO$147
- STELARA$136
- RESMETIROM$136
- Rosch-Uchida$135
- ZEPOSIA$115
- CERTUS 140 MICROWAVE ABLATION SYSTEM$106
How this compares
$357,164 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 26 | $638,680 |
| XifaxanRifaximin | 74 | $228,413 |
| OcalivaObeticholic Acid | 24 | $211,393 |
| VemlidyTenofovir Alafenamide | 55 | $72,780 |
| Ursodiol | 105 | $13,223 |
| Envarsus XrTacrolimus | 30 | $12,910 |
| Sirolimus | 23 | $7,396 |
| Entecavir | 29 | $6,499 |
| Tacrolimus | 48 | $4,820 |
| Mycophenolate Mofetil | 23 | $2,750 |
| Azathioprine | 35 | $1,949 |
| Lactulose | 36 | $1,196 |
| Spironolactone | 64 | $648 |
| Furosemide | 69 | $232 |
| Carvedilol | 26 | $222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $179,955 | $711,46081 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $50,053 | $228,41374 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $18,633 | $211,39324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 787 gastroenterology providers in Illinois.
Other gastroenterology in Burr Ridge
- Sujit JanardhanBurr Ridge$166K
- Irving WaxmanBurr Ridge$157K
- David RubinChicago$1.5M
- Stephen HanauerChicago$1.4M
- Steven FlammChicago$1.3M
- Amar NaikDes Plaines$1.2M
- Darren BrennerChicago$1.1M
- Jonathan RosenbergGurnee$1M
- Daksesh PatelEvanston$745K
- Russell CohenChicago$690K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.